Louis Bont retweeted
I recently wrote a piece on what you need to know about #RSV.
I discuss why RSV is surging now, where it is most deadly and why I’m optimistic that there may soon be a vaccine to protect children from this dangerous illness. Read more 👇
Respiratory syncytial virus, or RSV, is a common respiratory virus that was unknown to many until recently– yet it causes more than 100,000 deaths in children under 5 per year.
Here are four things you need to know about RSV: gates.ly/3A10Kg4
RSV vaccine development reaches endgame. #RSV #BMGF RSV vaccine development reaches endgame. sciencedirect.com/science/ar….
Worldwide hospital-acquired RSV infection causes 20% of all hospital RSV deaths. #RSV #BMGF medrxiv.org/content/10.1101/…
RSV immunizations enter the endgame. We must consider how to deliver them to those who need them most. By Ginsburg & Srikantiah thelancet.com/journals/langl…. #RSV #BMGF # ReSViNET
Louis Bont retweeted
Today is the start of ReSViNET’s 6th conference RSVVW’21 – “A Global Conference on Novel RSV Preventive and Therapeutic Interventions”!
👉resvinet.org/rsvvw21.html
#RSV #ReSViNET
The patient perspective first in the next EU-funded RSV project PROMISE. #RSV @NairHarish @HNohynek @ajpollard1 @p_openshaw.
Louis Bont retweeted
The @UMCUtrecht, @RIVM and @Nivel_research are proud partners within the new EU PROMISE network which will focus on RS virus spread patterns. It will also monitor effects of interventions that help to defend against #RSV (such as vaccination) bit.ly/3k2XiJP
@BontLouis
Louis Bont retweeted
Really excited to be working with leading #RSV scientists in Europe to pave the way for introduction of novel vaccines and therapeutics against RSV. @PROMISE_IMI builds on the successes of @RESCEUproject over past 5 years. @PagetPhd @HNohynek @ajpollard1 @p_openshaw @BontLouis
The new @IMI_JU Project “Preparing for RSV Immunisation and Surveillance in Europe” (#PROMISE_IMI) will take a major leap forward in the fight against #RSV. Join us in this inspiring journey we are about to start.
imi-promise.eu/wp-content/up…
Louis Bont retweeted
Very proud to share our new manuscript published in Clinical Infectious Diseases on #RSV-related infant community deaths! Many thanks to our amazing network of collaborators, we're truly grateful for all the time and efforts they put into our project!
academic.oup.com/cid/article…
Novel data about mortality due to RS-Virus outside the hospital. Register here to join FREE webinar on SEPT-17. #RSV #Fundacioninfant mcaevents.eventsair.com/resv…
Louis Bont retweeted
RSV changes over time in the airways of infected babies.
Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus | Nature Communications @Nature @RESCEUproject #RSV nature.com/articles/s41467-0…
RSV changes over time in the airways of infected babies.
Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus | Nature Communications @Nature @RESCEUproject #RSV nature.com/articles/s41467-0…
Painful lack of options to act. What can we do for our academic friends in Afghanistan?
Louis Bont retweeted
Fundamental insight in community mortality by RSV. Ten upcoming papers in Clin Infect Dis discussed in the resvinet.org webinar on SEP-17 open for registration. #RSV #BMGF mcaevents.eventsair.com/resv…
Fundamental insight in community mortality by RSV. Ten upcoming papers in Clin Infect Dis discussed in the resvinet.org webinar on SEP-17 open for registration. #RSV #BMGF mcaevents.eventsair.com/resv…
Louis Bont retweeted
Congrats to the BRONCHEU study team on their recent article publication in the Journal of Critical Care. BRONCHEU aims to investigate the amount & characteristics of #PICU admissions for viral bronchiolitis in Europe.
Read publication here: bit.ly/3jgbnT6
#Paediatrics
Louis Bont retweeted
1 billion doses today. But so much more to do.
Replying to @UniofOxford
Prof Sir Andy Pollard,'We pay tribute to the superhuman efforts of the teams at @AstraZeneca @SerumInstIndia and at sites around the world in producing a phenomenal number of doses 24 hrs a day & getting them to vaccine clinics in more than 170 countries.'

















